Literature DB >> 19101524

Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis.

Tomohito Kadota1, Tetsuro Shingo, Takao Yasuhara, Naoki Tajiri, Akihiko Kondo, Takamasa Morimoto, Wen Ji Yuan, Feifei Wang, Tanefumi Baba, Koji Tokunaga, Yasuyuki Miyoshi, Isao Date.   

Abstract

Parkinson's disease (PD) is characterized by degeneration of nigrostriatal dopaminergic neuronal systems. Several therapeutic tools for PD include medication using L-DOPA and surgeries such as deep brain stimulation are established. However, the therapies are considered as symptomatic therapy, but not basic remedy for PD and a new regenerative therapy would be desired to explore. In this study, the neuroprotective/rescue effects of erythropoietin (EPO), a well known hematopoietic hormone, on dopaminergic neurons were explored with neurogeneic potencies of EPO. EPO (100 IU/day) was continuously administered with micro-osmotic pump for a week to PD model of rats induced by intrastriatal 6-hydroxydopamine (6-OHDA) injection with subsequent behavioral and immunohistochemical investigations. The number of amphetamine-induced rotations of EPO-treated rats significantly decreased, compared to the control rats. The preservation of dopaminergic neurons of EPO-treated rats were confirmed by tyrosine hydroxylase staining and Fluoro-Gold staining. The number of bromodeoxyuridine (BrdU)/polysialic acid-neural cell adhesion molecule (PSA-NCAM) double positive cells in the subventricular zone of EPO treated rats significantly increased with migratory potencies to the damaged striatum,compared to the control rats. Furthermore, TUNEL staining and phosphorylated Akt staining revealed that the neuroprotective/rescue effects of EPO might be mediated by anti-apoptotic effects through the increase of phosphorylated Akt. These results suggest that continuous low dose infusion of EPO exerts neuroprotective/rescue effects with neurogeneic potentials. EPO might be a strong tool for PD therapy, although the further experiments should be added.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101524     DOI: 10.1016/j.brainres.2008.11.094

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

1.  pH responsive granulocyte colony-stimulating factor variants with implications for treating Alzheimer's disease and other central nervous system disorders.

Authors:  Pete Heinzelman; Jennifer A Schoborg; Michael C Jewett
Journal:  Protein Eng Des Sel       Date:  2015-04-15       Impact factor: 1.650

2.  Erythropoietin attenuates 6-hydroxydopamine-induced apoptosis via glycogen synthase kinase 3β-mediated mitochondrial translocation of Bax in PC12 cells.

Authors:  Xu-Hua Ge; Guo-Ji Zhu; De-Qin Geng; Zhi-Jun Zhang; Chun-Feng Liu
Journal:  Neurol Sci       Date:  2012-12       Impact factor: 3.307

3.  Systemic injection of recombinant human erythropoietin after focal cerebral ischemia enhances oligodendroglial and endothelial progenitor cells in rat brain.

Authors:  Young Jae Kim; Yong-Wook Jung
Journal:  Anat Cell Biol       Date:  2010-06-30

Review 4.  Erythropoietin for infants with hypoxic-ischemic encephalopathy.

Authors:  Ronald J McPherson; Sandra E Juul
Journal:  Curr Opin Pediatr       Date:  2010-04       Impact factor: 2.856

5.  Neuroprotection and CD131/GDNF/AKT Pathway of Carbamylated Erythropoietin in Hypoxic Neurons.

Authors:  Jing Ding; Jing Wang; Qin-Ying Li; Jie-Zhong Yu; Cun-Gen Ma; Xin Wang; Chuan-Zhen Lu; Bao-Guo Xiao
Journal:  Mol Neurobiol       Date:  2016-08-19       Impact factor: 5.590

6.  Regulation of endogenous neural stem/progenitor cells for neural repair-factors that promote neurogenesis and gliogenesis in the normal and damaged brain.

Authors:  Kimberly J Christie; Ann M Turnley
Journal:  Front Cell Neurosci       Date:  2013-01-18       Impact factor: 5.505

Review 7.  Regenerative medicine for epilepsy: from basic research to clinical application.

Authors:  Takao Yasuhara; Takashi Agari; Masahiro Kameda; Akihiko Kondo; Satoshi Kuramoto; Meng Jing; Tatsuya Sasaki; Atsuhiko Toyoshima; Susumu Sasada; Kenichiro Sato; Aiko Shinko; Takaaki Wakamori; Yu Okuma; Yasuyuki Miyoshi; Naoki Tajiri; Cesario V Borlongan; Isao Date
Journal:  Int J Mol Sci       Date:  2013-11-28       Impact factor: 5.923

Review 8.  Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives.

Authors:  Naoko Kaneko; Eisuke Kako; Kazunobu Sawamoto
Journal:  Front Cell Neurosci       Date:  2013-11-27       Impact factor: 5.505

9.  Erythropoietin improves neurobehavior by reducing dopaminergic neuron loss in a 6‑hydroxydopamine‑induced rat model.

Authors:  Chen Qi; Mingxin Xu; Jing Gan; Xinxin Yang; Na Wu; Lu Song; Weien Yuan; Zhenguo Liu
Journal:  Int J Mol Med       Date:  2014-06-17       Impact factor: 4.101

10.  Spinal cord stimulation exerts neuroprotective effects against experimental Parkinson's disease.

Authors:  Aiko Shinko; Takashi Agari; Masahiro Kameda; Takao Yasuhara; Akihiko Kondo; Judith Thomas Tayra; Kenichiro Sato; Tatsuya Sasaki; Susumu Sasada; Hayato Takeuchi; Takaaki Wakamori; Cesario V Borlongan; Isao Date
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.